Cargando…
Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy
Chimeric antigen receptor (CAR)-T cell therapy represents a landmark advance in personalized cancer treatment. CAR-T strategy generally engineers T cells from a specific patient with a new antigen-specificity, which has achieved considerable success in hematological malignancies, but scarce benefits...
Autores principales: | Liu, Zaoqu, Zhou, Zhaokai, Dang, Qin, Xu, Hui, Lv, Jinxiang, Li, Huanyun, Han, Xinwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475465/ https://www.ncbi.nlm.nih.gov/pubmed/36168626 http://dx.doi.org/10.7150/thno.76854 |
Ejemplares similares
-
Biological and pharmacological roles of m(6)A modifications in cancer drug resistance
por: Liu, Zaoqu, et al.
Publicado: (2022) -
Engineering neoantigen vaccines to improve cancer personalized immunotherapy
por: Liu, Zaoqu, et al.
Publicado: (2022) -
Multifaceted role of redox pattern in the tumor immune microenvironment regarding autophagy and apoptosis
por: Ren, Yuqing, et al.
Publicado: (2023) -
Exploring the roles of intestinal flora in enhanced recovery after surgery
por: Liu, Zaoqu, et al.
Publicado: (2023) -
Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors
por: Johnson, Abigail, et al.
Publicado: (2022)